1,3,4-Oxadiazole Sulfonamide Derivatives Containing Pyrazole Structures: Design, Synthesis, Biological Activity Studies, and Mechanism Study.

J Agric Food Chem

National Key Laboratory of Green Pesticide, Key Laboratory of Green Pesticide and Agricultural Bioengineering, Ministry of Education, Center for R&D of Fine Chemicals of Guizhou University, Guiyang 550025, China.

Published: February 2025


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Sulfonamide derivatives have been widely used for pesticide research in recent years. Herein, 1,3,4-oxadiazole sulfonamide derivatives containing a pyrazole structure were synthesized, and their structure-activity relationship was studied. Bioactivity tests showed the remarkable efficacy of most synthesized compounds. Especially for pv , A23 exhibited 100% inhibition at 100 mg/L, surpassing bismerthiazol (99.3%), and 90% inhibition at 50 mg/L, outperforming thiodiazole copper (84.5%), with an EC of 5.0 mg/L, markedly more active than bismerthiazol (23.9 mg/L) and thiodiazole copper (63.5 mg/L). Initial investigations into antimicrobial mechanisms involved a series of biochemical analyses, including bacterial growth rate analysis, scanning electron microscopy, bacterial biofilm formation experiments, and molecular docking analyses. Notably, A23 considerably inhibited the formation of biofilms, disrupting the integrity of bacterial cell membranes. Co-analysis of transcriptomics and proteomics revealed the capability of A23 to regulate pathways such as tryptophan metabolism and phenylpropanoid biosynthesis, enhancing the innate immunity of rice and activating its disease resistance. Thus, A23 emerges as a potential immunoinducible pesticide lead compound for the discovery of highly active immune-inducing agents.

Download full-text PDF

Source
http://dx.doi.org/10.1021/acs.jafc.4c05674DOI Listing

Publication Analysis

Top Keywords

sulfonamide derivatives
12
134-oxadiazole sulfonamide
8
derivatives pyrazole
8
thiodiazole copper
8
mg/l
5
pyrazole structures
4
structures design
4
design synthesis
4
synthesis biological
4
biological activity
4

Similar Publications

CYP72A15 confers resistance against penoxsulam to Echinochloa phyllopogon.

Pestic Biochem Physiol

November 2025

Shenyang Agricultural University, College of Plant Protection, Shenyang, Liaoning 110866, PR China. Electronic address:

As the weed Echinochloa phyllopogon has rapidly developed multi- and cross-resistance to several herbicides, we aimed to determine the mechanism underlying penoxsulam resistance in weeds. There was no target mutation in the tested population, and P450 enzyme activity was significantly higher in the penoxsulam-treated resistant population, confirming that non-target-site resistance was dominant. The antioxidant enzyme activity of the resistant population was higher than that of the sensitive population following the application of the penoxsulam and cleared HO faster.

View Article and Find Full Text PDF

Tilorone, a 9-fluorenone scaffold-based molecule, is a known broad-spectrum antiviral with an IC of 180 nM against SARS-CoV-2, but its mechanism is not known. In the present study, we found it to have weak activity against PLpro (IC = 30.7 ± 7.

View Article and Find Full Text PDF

Compounds that possess a benzene sulfonamide structure are utilized in a wide range of fields. Benzene bissulfonamides are also important compounds in the field of organic and medicinal chemistry. Based on these features, a series of benzene bissulfonamides were synthesized in moderate yields starting from 3-methylanisole.

View Article and Find Full Text PDF

Transcriptional enhanced associate domain (TEAD), overexpressed in hepatocellular carcinoma (HCC) and inversely correlated to prognosis, has emerged as a promising target for HCC therapy. To date, no small-molecule inhibitors targeting TEAD have been reported for HCC treatment. In this study, a bioinformatic analysis has been performed and has demonstrated that TEAD is a promising target for therapeutic intervention in HCC.

View Article and Find Full Text PDF

Direct-acting antivirals (DAAs) have transformed hepatitis C virus (HCV) treatment in Australia since their inclusion on the Pharmaceutical Benefits Scheme (PBS) in 2016. Treatment has shifted from genotype-specific to pan-genotypic regimens, with glecaprevir/pibrentasvir and sofosbuvir/velpatasvir now recommended in clinical guidelines. This study examined trends in DAA dispensing in light of evolving treatment regimens.

View Article and Find Full Text PDF